Enduring Edge Annual Report

Overview

The report presents FY18 as a landmark year for Biocon, led by U.S. approval of its Ogivri biosimilar Trastuzumab. It reports that renewable energy reached 39% of total power consumption and that the eLAJ network expanded to 21 smart clinics. The sustainability section also describes environmental conservation and community healthcare initiatives.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018
Period: 1 April 2017 – 31 March 2018
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services